News

Ideas That Generate Results

Cancer is posing a significant and continuously growing burden on healthcare systems all across the world. This is driven mainly by escalating cancer drug budgets. Biosimilars can be a suitable and relatively cheaper option for the treatment of cancer. The available evidence indicates that biosimilars approved by regulatory authorities offer a safe and effective alternative to originator biological therapies. They also offer potentially significant cost savings to healthcare payers. The greater affordability of biosimilars may also result in clinical benefits, through earlier and wider appropriate therapy use and release of funding to be used elsewhere in clinical care. All these factors are encouraging biopharmaceutical companies to develop more biosimilars for the treatment of cancer.
 
In 2015, the USFDA approved a biosimilar, Zarxio, which is being developed by Sandoz. Zarxio is the first biosimilar to be approved in US. This biosimilar is intended for the treatment of patients receiving myelosuppressive chemotherapy, patients suffering from acute myeloid leukemia, patients with cancer undergoing bone marrow transplantation, patients undergoing autologous peripheral blood progenitor cell collection and therapy, and patients with severe chronic neutropenia.
 
According to new report by RNCOS, named, “Global Biosimilar Market Outlook 2022”, apart from the approved biosimilars, various biopharmaceutical companies are developing a strong pipeline of biosimilars for the treatment of various forms of cancer. For instance, Mylan and Biocon are co-developing a biosimilar Trastuzumab. This biosimilar is supposed to be a treatment option to treat certain HER2-positive breast and gastric cancers. These companies, recently, announced that the European Medicines Agency has accepted for review Mylan’s Marketing Authorization Application for this biosimilar. It is anticipated that this may be the first MAA for a Trastuzumab biosimilar accepted by the EMA for review.
 
Furthermore, Amgen is developing two biosimilars, ABP 980 and ABP 215, which are in Phase III of clinical trials. ABP 980 is being developed for the treatment of breast cancer and gastric cancer. Moreover, ABP 215 is being developed for the treatment of colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer. Apart from these, there are other biosimilars which are in pre-clinical stages of development. Such a strong biosimilar pipeline, once approved, will help in bringing down the cost of cancer treatment.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM857.htm
 
Check Related REPORTS on:  http://www.rncos.com/Healthcare_Industry.htm